View Item 

Show simple item record

Impact of biochemical failure classification on clinical outcome: A secondary analysis of Radiation Therapy Oncology Group 9202 and 9413
dc.contributor.authorHamstra, Daniel A.en_US
dc.contributor.authorBae, Kyounghwaen_US
dc.contributor.authorHanks, Geralden_US
dc.contributor.authorHu, Chenen_US
dc.contributor.authorShipley, William U.en_US
dc.contributor.authorPan, Charlie C.en_US
dc.contributor.authorRoach, Macken_US
dc.contributor.authorLawton, Colleen A.en_US
dc.contributor.authorSandler, Howard M.en_US
dc.date.accessioned2015-04-02T15:12:19Z
dc.date.available2016-05-10T20:26:28Zen
dc.date.issued2015-03-15en_US
dc.identifier.citationHamstra, Daniel A.; Bae, Kyounghwa; Hanks, Gerald; Hu, Chen; Shipley, William U.; Pan, Charlie C.; Roach, Mack; Lawton, Colleen A.; Sandler, Howard M. (2015). "Impact of biochemical failure classification on clinical outcome: A secondary analysis of Radiation Therapy Oncology Group 9202 and 9413." Cancer 121(6): 844-852.en_US
dc.identifier.issn0008-543Xen_US
dc.identifier.issn1097-0142en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/110839
dc.publisherJohn Wiley & Sonsen_US
dc.subject.otherprostate‐specific antigen failureen_US
dc.subject.otherradiotherapyen_US
dc.subject.otherprostate‐specific antigenen_US
dc.titleImpact of biochemical failure classification on clinical outcome: A secondary analysis of Radiation Therapy Oncology Group 9202 and 9413en_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPublic Healthen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/110839/1/cncr29146.pdf
dc.identifier.doi10.1002/cncr.29146en_US
dc.identifier.sourceCanceren_US
dc.identifier.citedreferencePickles T. Prostate‐specific antigen (PSA) bounce and other fluctuations: which biochemical relapse definition is least prone to PSA false calls? An analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant androgen deprivation therapy. Int J Radiat Oncol Biol Phys. 2006; 64: 1355 ‐ 1359.en_US
dc.identifier.citedreferenceRoach M III, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG‐ASTRO Phoenix consensus conference. Int J Radiat Oncol Biol Phys. 2006; 65: 965 ‐ 974.en_US
dc.identifier.citedreferenceRoach M III, DeSilvio M, Lawton C, et al. Phase III trial comparing whole‐pelvic versus prostate‐only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol. 2003; 21: 1904 ‐ 1911.en_US
dc.identifier.citedreferenceHanks GE, Pajak TF, Porter A, et al. Phase III trial of long‐term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92‐02. J Clin Oncol. 2003; 21: 3972 ‐ 3978.en_US
dc.identifier.citedreferenceRoach M III, Marquez C, Yuo HS, et al. Predicting the risk of lymph node involvement using the pre‐treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 1994; 28: 33 ‐ 37.en_US
dc.identifier.citedreferenceKaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457 ‐ 481.en_US
dc.identifier.citedreferenceMantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966; 50: 163 ‐ 170.en_US
dc.identifier.citedreferenceKalbfleisch J, Prentice R. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley & Sons; 1980.en_US
dc.identifier.citedreferenceGray R. A class of K‐sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988; 16: 1141 ‐ 1154.en_US
dc.identifier.citedreferenceCox D. Regression models and life tables. J R Stat Soc Ser B. 1972; 34: 187 ‐ 229.en_US
dc.identifier.citedreferenceFine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999; 94: 496 ‐ 509.en_US
dc.identifier.citedreferenceKleinbaum DG, Klein M. Survival Analysis: A Self‐Learning Text. 3rd ed. New York, NY: Springer‐Verlag; 2012.en_US
dc.identifier.citedreferenceAlmeras C, Zerbib M, Eschwege F, Debre B. Nadir PSA and kinetics of PSA decline between the 3rd and 6th month after external beam radiotherapy for T1 T2 Nx M0 localized prostate cancer: value of the prediction of the risk of biological progression [in French]. Prog Urol. 2002; 12: 219 ‐ 225.en_US
dc.identifier.citedreferenceCury FL, Hunt D, Roach M III, et al. Prostate‐specific antigen response after short‐term hormone therapy plus external‐beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413. Cancer. 2013; 119: 1999 ‐ 2004.en_US
dc.identifier.citedreferenceLoblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen‐sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007; 25: 1596 ‐ 1605.en_US
dc.identifier.citedreferenceD'Ambrosio DJ, Ruth K, Horwitz EM, Uzzo RG, Pollack A, Buyyounouski MK. How can men destined for biochemical failure after androgen deprivation and radiotherapy be identified earlier? Int J Radiat Oncol Biol Phys. 2008; 70: 1487 ‐ 1491.en_US
dc.identifier.citedreferenceJohnson SB, Jackson WC, Murgic J, Feng FY, Hamstra DA. Time to nadir PSA: of popes and PSA—the immortality bias. Am J Clin Oncol. 2013. Sep 21 [Epub ahead of print]en_US
dc.identifier.citedreferenceD'Amico AV, Chen MH, de Castro M, et al. Surrogate endpoints for prostate cancer‐specific mortality after radiotherapy and androgen suppression therapy in men with localized or locally advanced prostate cancer: an analysis of two randomised trials. Lancet Oncol. 2012; 13: 189 ‐ 195.en_US
dc.identifier.citedreferenceShilkrut M, McLaughlin PW, Merrick GS, Vainshtein JM, Feng FY, Hamstra DA. Interval to biochemical failure predicts clinical outcomes in patients with high‐risk prostate cancer treated by combined‐modality radiation therapy. Int J Radiat Oncol Biol Phys. 2013; 86: 721 ‐ 728.en_US
dc.identifier.citedreferenceMaffezzini M, Bossi A, Collette L. Implications of prostate‐specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer. Eur Urol. 2007; 51: 605 ‐ 613.en_US
dc.identifier.citedreferenceValicenti RK, DeSilvio M, Hanks GE, et al. Posttreatment prostatic‐specific antigen doubling time as a surrogate endpoint for prostate cancer‐specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92‐02. Int J Radiat Oncol Biol Phys. 2006; 66: 1064 ‐ 1071.en_US
dc.identifier.citedreferenceShipley WU, Desilvio M, Pilepich MV, et al. Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: a secondary analysis of RTOG protocol 86‐10. Int J Radiat Oncol Biol Phys. 2006; 64: 1162 ‐ 1167.en_US
dc.identifier.citedreferenceBuyyounouski MK, Pickles T, Kestin LL, Allison R, Williams SG. Validating the interval to biochemical failure for the identification of potentially lethal prostate cancer. J Clin Oncol. 2012; 30: 1857 ‐ 1863.en_US
dc.identifier.citedreferenceDenham JW, Steigler A, Wilcox C, et al. Time to biochemical failure and prostate‐specific antigen doubling time as surrogates for prostate cancer‐specific mortality: evidence from the TROG 96.01 randomised controlled trial. Lancet Oncol. 2008; 9: 1058 ‐ 1068.en_US
dc.identifier.citedreferenceKapadia NS, Olson K, Sandler HM, Feng FY, Hamstra DA. Interval to biochemical failure as a biomarker for cause‐specific and overall survival after dose‐escalated external beam radiation therapy for prostate cancer. Cancer. 2012; 118: 2059 ‐ 2068.en_US
dc.identifier.citedreferenceConsensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys. 1997; 37: 1035 ‐ 1041.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr29146.pdf
Size:
262.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.